Our portfolio ranges from clinical proof of concept to final products (drugs, medical devices, dietary supplements) under trademarks ready to be marketed.
For further scientific or commercial information, please contact us.
Gynaecological biotherapeutic range:
We are developping the first live biotherapeutic product by vaginal route: Gynophilus®. With this know-how combined with our expertise in the vaginal microbiota, we have developed a complete range of biotherapeutic products for women and their intimate comfort.
Gastroenterological biotherapeutic range:
We are the first having conceived a microbiota-derived live medication for the symptomatic treatment of diarrhoea. Since then, we have developed a range of biotherapeutic products targeting both diarrhoea and digestive well-being.
Premature infants are lacking a mature immune system and feature intestinal dysbiosis, translating in complications such as Necrotizing Enterocolitis ( characterised by injuries along the intestinal tract ranging from mucosal lesion to necrosis and perforation), intestinal bleeding, septicaemia…
We are looking for options to help them starting their life with a healthy microbiome, participating to their efforts to thrive.
Diabetes: side effects associated with metformin
According to the International Diabetes Federation, 415 million people have diabetes worldwide. This qualifies the phenomenon as a real pandemic, as the progression is considerable. In fact, the WHO predicts 622 million diabetics by 2040.
The side effects of metformin (one of the mostly used antidiabetic agents) brought us tu study the disease from the microbiota perspective.
We are developing a live biotherapeutic solution for the relief of such side effects.